title: Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study.
abstract: We investigated the long-term effect of trastuzumab, a monoclonal antibody against the Her2 signalling pathway, on QT dispersion in female patients with early-stage breast cancer. A total of 46 eligible patients with early-stage breast cancer were divided into two groups according to whether they were treated with trastuzumab: Group 1 (n = 32, patients with Her2-positive tumours who were treated with trastuzumab) and Group 2 (n = 14, patients with Her2-negative tumours who were not treated with trastuzumab). The both groups were compared using QT interval measurements. Patients with breast cancer treated with trastuzumab after an anthracycline-based regimen exhibited a significantly higher QTd than non-treated patients (0.064 ± 0.023 s vs. 0.051 ± 0.016 s, respectively) (P = 0.034). The mean increases in QTd and QTcd for Group 1 patients after paclitaxel-trastuzumab combination treatment (0.021 ± 0.011 and 0.022 ± 0.014 s, respectively) are significantly different than the mean increases in QT and QTcd after an anthracycline-based regimen (0.005 ± 0.003 and 0.006 ± 0.008 s) in the same group (P = 0.0246), compared with initial measurements. It has been concluded that the relationship between increased QTd measurements and trastuzumab treatment for 12 weeks in an adjuvant setting for patients with early-stage breast cancer is independent from other study variables. We suggested that long-term treatment with trastuzumab significantly prolonged the QT interval and increased QTd in patients with breast cancer.
authors: Department of Medical Oncology, Mugla University Education and Research Hospital, Mugla, Turkey. ozgurtanriverdi@hotmail.com
authors: Ozgur
authors: O
authors: Tanriverdi
authors: Nezih
authors: N
authors: Meydan
authors: Sabri
authors: S
authors: Barutca
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004562:Electrocardiography / Q000187:drug effects*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D011878:Radiotherapy / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D013995:Time; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide; D015251:Epirubicin; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human